{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:16:45Z","timestamp":1792790205181,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Foundation of Korea (NRF) grant funded by the Korea government","award":["RS-2023-NR076559"],"award-info":[{"award-number":["RS-2023-NR076559"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-62066-5","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:34:32Z","timestamp":1783928072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A pooled population pharmacokinetic analysis of ticagrelor in acute coronary syndrome using simulated data"],"prefix":"10.1038","volume":"16","author":[{"given":"Ji Woo","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heungjo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyongkuk","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8408-5907","authenticated-orcid":false,"given":"Min Jung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"62066_CR1","first-page":"562","volume":"37","author":"R Fuller","year":"2012","unstructured":"Fuller, R. & Chavez, B. Ticagrelor (brilinta), an antiplatelet drug for acute coronary syndrome. P T. 37, 562\u2013568 (2012).","journal-title":"P T"},{"key":"62066_CR2","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1182\/hematology.2020000151","volume":"2020","author":"G D Barnes","year":"2020","unstructured":"D. Barnes, G. Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematol. Am. Soc. Hematol. Educ. Program. 2020, 642\u2013648 (2020).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"62066_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","volume":"124","author":"KW Mahaffey","year":"2011","unstructured":"Mahaffey, K. W. et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 124, 544\u2013554 (2011).","journal-title":"Circulation"},{"key":"62066_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.emc.2022.06.008","volume":"40","author":"J Atwood","year":"2022","unstructured":"Atwood, J. Management of acute coronary syndrome. Emerg. Med. Clin. North. Am. 40, 693\u2013706 (2022).","journal-title":"Emerg. Med. Clin. North. Am."},{"key":"62066_CR5","doi-asserted-by":"publisher","first-page":"e2134322","DOI":"10.1001\/jamanetworkopen.2021.34322","volume":"4","author":"LP Dawson","year":"2021","unstructured":"Dawson, L. P. et al. Assessment of pretreatment with oral P2Y12 inhibitors and cardiovascular and bleeding outcomes in patients with non-ST elevation acute coronary syndromes: a systematic review and meta-analysis. JAMA Netw. Open. 4, e2134322. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.34322 (2021).","journal-title":"JAMA Netw. Open."},{"key":"62066_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/FJC.0000000000001442","volume":"82","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. The plasma concentration of ticagrelor and aspirin as a predictor of bleeding complications in Chinese acute coronary syndrome patients with dual antiplatelet therapy: a prospective observational study. J. Cardiovasc. Pharmacol. 82, 148\u2013156. https:\/\/doi.org\/10.1097\/FJC.0000000000001442 (2023).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"62066_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","volume":"404","author":"M Valgimigli","year":"2024","unstructured":"Valgimigli, M. et al. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet 404, 937\u2013948. https:\/\/doi.org\/10.1016\/S0140-6736(24)01616-7 (2024).","journal-title":"Lancet"},{"key":"62066_CR8","doi-asserted-by":"publisher","unstructured":"Rao, S. V. et al. ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 151, e771\u2013e862; (2025). https:\/\/doi.org\/10.1161\/CIR.0000000000001309 (2025).","DOI":"10.1161\/CIR.0000000000001309"},{"key":"62066_CR9","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne, R. A. et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur. Heart J. 44, 3720\u20133826 (2023).","journal-title":"Eur. Heart J."},{"key":"62066_CR10","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2020","unstructured":"Collet, J. P. et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 42, 1289\u20131367 (2020).","journal-title":"Eur. Heart J."},{"key":"62066_CR11","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","volume":"391","author":"JY Hahn","year":"2018","unstructured":"Hahn, J. Y. et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet 391, 1274\u20131284 (2018).","journal-title":"Lancet"},{"key":"62066_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40292-024-00635-3","volume":"31","author":"AR Khalid","year":"2024","unstructured":"Khalid, A. R. et al. Safety of clopidogrel vs. ticagrelor in dual antiplatelet therapy regimens for high-bleeding risk acute coronary syndrome patients: a comprehensive meta-analysis of adverse outcomes. High. Blood Press. Cardiovasc. Prev. 31, 141\u2013155. https:\/\/doi.org\/10.1007\/s40292-024-00635-3 (2024).","journal-title":"High. Blood Press. Cardiovasc. Prev."},{"key":"62066_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12959-023-00559-3","volume":"22","author":"P Wei","year":"2024","unstructured":"Wei, P., Wang, X., Fu, Q. & Cao, B. Progress in the clinical effects and adverse reactions of ticagrelor. Thromb. J. 22, 8. https:\/\/doi.org\/10.1186\/s12959-023-00559-3 (2024).","journal-title":"Thromb. J."},{"key":"62066_CR14","doi-asserted-by":"publisher","first-page":"666","DOI":"10.5414\/CP202549","volume":"54","author":"J Li","year":"2016","unstructured":"Li, J., Tang, W., Storey, R. F., Husted, S. & Teng, R. Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. Int. J. Clin. Pharmacol. Ther. 54, 666\u2013674 (2016).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"62066_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.4070\/kcj.2018.0166","volume":"48","author":"J Kang","year":"2018","unstructured":"Kang, J. & Kim, H. S. The evolving concept of dual antiplatelet therapy after percutaneous coronary intervention: focus on unique feature of East Asian and \u2018Asian paradox\u2019. Korean Circ. J. 48, 537\u2013551 (2018).","journal-title":"Korean Circ. J."},{"key":"62066_CR16","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/cpt.3048","volume":"114","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Model-informed dosing regimen of ticagrelor in Chinese patients with acute coronary syndrome. Clin. Pharmacol. Ther. 114, 1342\u20131349 (2023).","journal-title":"Clin. Pharmacol. Ther."},{"key":"62066_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13318-023-00867-z","volume":"49","author":"S Zheng","year":"2024","unstructured":"Zheng, S. et al. Ticagrelor steady-state trough concentration in Chinese patients undergoing percutaneous coronary intervention. Eur. J. Drug Metab. Pharmacokinet. 49, 33\u201342 (2024).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"62066_CR18","doi-asserted-by":"publisher","first-page":"11746","DOI":"10.1038\/s41598-018-29619-9","volume":"8","author":"P Adamski","year":"2018","unstructured":"Adamski, P. et al. Metabolism of ticagrelor in patients with acute coronary syndromes. Sci. Rep. 8, 11746 (2018).","journal-title":"Sci. Rep."},{"key":"62066_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/ehjcvp\/pvab042","volume":"8","author":"F Franchi","year":"2022","unstructured":"Franchi, F. et al. Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. Eur. Heart J. Cardiovasc. Pharmacother. 8, 452\u2013461 (2022).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother"},{"key":"62066_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40262-023-01335-2","volume":"63","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Population pharmacokinetic\/pharmacodynamic models for P2Y12 inhibitors: a systematic review and clinical appraisal using exposure simulation. Clin. Pharmacokinet. 63, 303\u2013316 (2024).","journal-title":"Clin. Pharmacokinet."},{"key":"62066_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.5414\/CP202748","volume":"55","author":"D R\u00f6shammar","year":"2017","unstructured":"R\u00f6shammar, D., Bergstrand, M., Andersson, T., Storey, R. F. & Hamr\u00e9n, B. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction. Int. J. Clin. Pharmacol. Ther. 55, 416\u2013424 (2017).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"62066_CR22","doi-asserted-by":"publisher","first-page":"1143835","DOI":"10.3389\/fendo.2023.1143835","volume":"14","author":"M Konstandi","year":"2023","unstructured":"Konstandi, M. & Johnson, E. O. Age-related modifications in CYP-dependent drug metabolism: role of stress. Front. Endocrinol. (Lausanne). 14, 1143835 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"62066_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/03602532.2020.1859528","volume":"53","author":"M Barrangou-Poueys-Darlas","year":"2021","unstructured":"Barrangou-Poueys-Darlas, M. et al. CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation. Drug Metab. Rev. 53, 30\u201344. https:\/\/doi.org\/10.1080\/03602532.2020.1859528 (2021).","journal-title":"Drug Metab. Rev."},{"key":"62066_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bcp.13812","volume":"85","author":"M \u00c5strand","year":"2019","unstructured":"\u00c5strand, M. et al. Pharmacokinetic\u2013pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Br. J. Clin. Pharmacol. 85, 413\u2013421 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"62066_CR25","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1111\/bcp.15422","volume":"88","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome. Br. J. Clin. Pharmacol. 88, 4870\u20134880 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"62066_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s13318-025-00957-0","volume":"50","author":"H Matsui","year":"2025","unstructured":"Matsui, H. et al. Evaluation of the effect of ticagrelor dose interruption and treatment resumption with or without bolus doses through population PK\/PD simulation. Eur. J. Drug Metab. Pharmacokinet. 50, 409\u2013418 (2025).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"62066_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/ehjcvp\/pvad063","volume":"9","author":"AR Munaf\u00f2","year":"2023","unstructured":"Munaf\u00f2, A. R. et al. External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother. 9, 709\u2013721. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad063 (2023).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother"},{"key":"62066_CR28","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1093\/eurheartj\/ehac284","volume":"43","author":"M Valgimigli","year":"2022","unstructured":"Valgimigli, M. et al. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur. Heart J. 43, 3100\u20133114. https:\/\/doi.org\/10.1093\/eurheartj\/ehac284 (2022).","journal-title":"Eur. Heart J."},{"key":"62066_CR29","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran, R. et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl. J. Med. 381, 2032\u20132042 (2019).","journal-title":"N Engl. J. Med."},{"key":"62066_CR30","unstructured":"Galli, M. et al. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis. BMJ 384, e075168 (2024)."},{"key":"62066_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/bmjebm-2023-112476","volume":"29","author":"O De Filippo","year":"2024","unstructured":"De Filippo, O. et al. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis. BMJ Evid. Based Med. 29, 171\u2013186 (2024).","journal-title":"BMJ Evid. Based Med."},{"key":"62066_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/09537104.2020.1732328","volume":"32","author":"J Shi","year":"2021","unstructured":"Shi, J. et al. Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR). Platelets 32, 120\u2013129 (2021).","journal-title":"Platelets"},{"key":"62066_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/ehjcvp\/pvae054","volume":"10","author":"R Piccolo","year":"2024","unstructured":"Piccolo, R. et al. Ticagrelor 60 vs. 90\u00a0mg in elderly ACS patients undergoing PCI: a randomized, crossover trial. Eur. Heart J. Cardiovasc. Pharmacother. 10, 578\u2013587. https:\/\/doi.org\/10.1093\/ehjcvp\/pvae054 (2024).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother"},{"key":"62066_CR34","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","volume":"388","author":"G Cayla","year":"2016","unstructured":"Cayla, G. et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 388, 2015\u20132022 (2016).","journal-title":"Lancet"},{"key":"62066_CR35","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41569-023-00901-2","volume":"20","author":"DA Gorog","year":"2023","unstructured":"Gorog, D. A. et al. De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a consensus statement from an international expert panel on coronary thrombosis. Nat. Rev. Cardiol. 20, 830\u2013844 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"62066_CR36","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","volume":"71","author":"FM Notarangelo","year":"2018","unstructured":"Notarangelo, F. M. et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO trial. J. Am. Coll. Cardiol. 71, 1869\u20131877 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"62066_CR37","doi-asserted-by":"publisher","first-page":"e18109","DOI":"10.7717\/peerj.18109","volume":"12","author":"X Hu","year":"2024","unstructured":"Hu, X., Wang, P., Zeng, D. & Hu, G. X. The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population. PeerJ 12, e18109. https:\/\/doi.org\/10.7717\/peerj.18109 (2024).","journal-title":"PeerJ"},{"key":"62066_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/psp4.12467","volume":"8","author":"A Elmokadem","year":"2019","unstructured":"Elmokadem, A., Riggs, M. M. & Baron, K. T. Quantitative systems pharmacology and physiologically-based pharmacokinetic modeling with mrgsolve: a hands-on tutorial. CPT Pharmacometrics Syst. Pharmacol. 8, 883\u2013893 (2019).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"62066_CR39","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s10928-006-9033-1","volume":"33","author":"SJ Tannenbaum","year":"2006","unstructured":"Tannenbaum, S. J., Holford, N. H. G., Lee, H., Peck, C. C. & Mould, D. R. Simulation of correlated continuous and categorical variables using a single multivariate distribution. J. Pharmacokinet. Pharmacodyn. 33, 773\u2013794 (2006).","journal-title":"J. Pharmacokinet. Pharmacodyn"},{"key":"62066_CR40","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1124\/dmd.110.032250","volume":"38","author":"R Teng","year":"2010","unstructured":"Teng, R., Oliver, S., Hayes, M. A. & Butler, K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab. Dispos. 38, 1514\u20131521 (2010).","journal-title":"Drug Metab. Dispos."},{"key":"62066_CR41","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl. J. Med. 372, 1791\u20131800 (2015).","journal-title":"N Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62066-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62066-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62066-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:03:11Z","timestamp":1791896591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62066-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["62066"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-62066-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was based entirely on simulated pharmacokinetic data derived from previously published sources. As no direct involvement of human participants or animal experiments was required, ethical review and approval were not applicable.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used Claude (Anthropic) to assist with drafting and editing the manuscript text. The authors reviewed, edited, and take full responsibility for the content of the publication.This study was based","order":3,"name":"Ethics","label":"Use of AI-assisted tools","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32019"}}